Peptide 141 is a neuropeptide that binds to melanocortin receptors in the brain. These receptors control sexual function, appetite, and immunity among other physiologic activities.
Originally discovered while testing a peptide that would darken skin, this melanocortin agonist was found to increase spontaneous erections in male test subjects. PT-141 has since been used to treat erectile dysfunction and female hypoactive sexual desire disorder in premenopausal women.
The hormone PT-141 works by stimulating and activating the MC-1, MC-3, and MC-4 melanocortin receptors, which are located in the brain and play a role in regulating a number of physiologic functions. These include skin pigmentation, appetite, and immune system responses to stress, arousal, and homeostasis.
It is also theorized that PT-141 may also have the ability to stimulate dopamine release. Dopamine plays a significant role in sexual motivation, as well as in the production of hormones that enhance sex performance and stimulate libido.
Unlike Cialis (tadalafil) and Viagra (sildenafil), PT-141 primarily works in the brain to enhance arousal, desire, and satisfaction with sex. As such, it is a good treatment for men and women suffering from both erectile dysfunction and female hypoactive desire disorder.
PT-141 is a non-selective agonist of the melanocortin receptors MC1 through MC4. It increases blood flow to the penis or vagina and clitoris. This allows for the increased arousal, sensitivity, and stimulation that is necessary to return the sexual passion and intimacy you crave. In addition, PT-141 is non-addictive and does not cause any adverse side effects when injected subcutaneously into the stomach region or thigh.